Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

DISEASE CHARACTERISTICS:

• Histologically confirmed melanoma
• Metastatic disease
• Measurable or evaluable disease
• Disease progression during or after prior interleukin-2 (IL-2) OR ineligible to receive high-dose IL-2* OR has disease burden for which IL-2 is not indicated* NOTE: *If patient did not receive prior IL-2, must have progressed after prior standard first-line therapy (e.g., metastasectomy for single lesions or dacarbazine)
• HLA-A*0201-positive disease

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• ECOG 0-2

Life expectancy

• At least 3 months

Hematopoietic

• Absolute neutrophil count > 1,000/mm^3*
• Absolute lymphocyte count ≥ 200/mm^3*
• Platelet count > 100,000/mm^3
• No proliferative hematologic disease NOTE: *For 2 consecutive readings performed on 2 different days

Hepatic

• AST and ALT < 3 times upper limit of normal (ULN)
• PT/PTT ≤ 1.5 times ULN
• Hepatitis B negative
• Positive hepatitis B serology indicative of prior immunization (i.e., positive for antibody against hepatitis B surface antigen AND negative for antibody against hepatitis B core antigen) allowed
• Hepatitis C negative

Renal

• Creatinine ≤ 1.4 mg/dL

Cardiovascular

• Ejection fraction > 45% by MUGA for patients ≥ 50 years of age OR with a history of cardiac disease
• No resting blood pressure > 140/90 mm Hg with standard antihypertensive therapy

Pulmonary

• DLCO/VA and FEV_1 > 50% of predicted on pulmonary function test for smokers OR for patients with clinical evidence of compromised pulmonary function
• No history of severe asthma

Immunologic

• HIV negative
• No history of autoimmune disease
• No splenomegaly

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No other medical or psychiatric disease that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

• See Disease Characteristics
• More than 4 weeks since prior cytokines
• No prior allogeneic hematopoietic stem cell transplantation
• No concurrent growth factors
• No concurrent monoclonal antibodies
• No other concurrent immunotherapy
• No other concurrent cytokines
• No other concurrent biologic agents

Chemotherapy

• See Disease Characteristics
• No prior intensive myeloablative chemotherapy
• No concurrent chemotherapy

Endocrine therapy

• More than 2 weeks since prior systemic corticosteroids for more than 72 hours in duration
• No concurrent systemic steroids

Radiotherapy

• Not specified

Surgery

• See Disease Characteristics
• No prior splenectomy
• No prior solid organ transplantation

Other

• More than 4 weeks since prior cytotoxic therapy
• No other concurrent cytotoxic therapy
• No concurrent chronic anticoagulation therapy (e.g., high-dose warfarin, heparin, or aspirin)
• Concurrent low-dose warfarin (1-2 mg) allowed
• No concurrent chronic medication for asthma
• No concurrent immunosuppressive therapy